Anti-Hu CD334 Purified

Anti-Hu CD334 Purified
Regulatory status
RUO
Antigen
CD334
Clone
4FR6D3
Format
Purified
Reactivity
Human
Application
FC (QC tested), ICC
Variant
0.1 mg
11-591-C100
In stock

0.025 mg
11-591-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody 4FR6D3 reacts with CD334, the fibroblast growth factor receptor 4, which is an approximately 88 kDa receptor tyrosine kinase expressed in variety of tissues.
Application
FC (QC tested), ICC
Reactivity
Human
Immunogen
NIH 3T3 cells transfected with full length human CD334
Other names
FGFR4, TKF, JTK2, FGFR-4
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

General references:

Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL: FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes. 2007 Oct;56(10):2501-10.
PubMed
Zhao P, Caretti G, Mitchell S, McKeehan WL, Boskey AL, Pachman LM, Sartorelli V, Hoffman EP: Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem. 2006 Jan 6;281(1):429-38.
PubMed
Yang YC, Lu ML, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Figlin RA, Belldegrun A, Cordon-Cardo C, Zhang ZF: Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer. 2006 Dec 4;95(11):1455-8.
PubMed
Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002 Feb 1;62(3):840-7.
PubMed
Vainikka S, Partanen J, Bellosta P, Coulier F, Birnbaum D, Basilico C, Jaye M, Alitalo K: Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J. 1992 Dec;11(12):4273-80.
PubMed
Partanen J, Mäkelä TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L, Alitalo K: FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J. 1991 Jun;10(6):1347-54.
PubMed
Variant
0.1 mg
11-591-C100
In stock

0.025 mg
11-591-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock